Abstract: The present disclosure relates to the field of biopharmaceuticals and provides a nerve growth factor (NGF) fusion protein and a preparation method and use thereof. The fusion protein has a general formula represented by A-B or A-L-B, wherein A is a nerve growth factor, L is a linker peptide, and B is an Fc moiety of IgG, or an analogue of the Fc moiety of IgG, or a fragment of the Fc moiety of IgG. The fusion protein of the present disclosure has the following advantages over a wild-type NGF: higher biological activity, a half-life extended more than 17 times, greatly reduced administration frequency, and significantly increased efficacy.
Abstract: The present invention elates to the applications of neuregulin in the preparation of drugs for preventing, treating or delaying the ischemia-reperfusion injury (IRI) in mammals, particularly in humans. In particular, the present invention provides the neuregulin based compositions and methods for preventing, treating or delaying the myocardial ischemia-reperfusion injury. Specifically, although it has been shown in cytological experiments, animal studies and clinical trials that neuregulin can improve the cytoskeleton structure of myocytes and cardiac function, it is still unknown whether neuregulin has effects on the myocardial ischemia-reperfusion injury. The present invention proves that neuregulin reduces the infarction size in the rat IRI model, which indicates that neuregulin can be used for preventing, treating or delaying the myocardial ischemia-reperfusion injury.
Abstract: The present invention provides a method with which it is possible to directly induce nervous system cells efficiently and in a short amount of time. Because the method is easy to scale up and is not affected by the characteristics or background of the somatic cells used as material, the method enables the stable supply of nervous system cells. The nervous system cells obtained by the method are useful in various fields of research and healthcare.
Type:
Grant
Filed:
January 18, 2016
Date of Patent:
October 10, 2023
Assignees:
KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, KATAOKA CORPORATION
Abstract: Human pluripotent stem cells are differentiated in vitro into oligodendro-spheroids comprising oligodendrocytes for use in analysis, screening programs, and the like.
Type:
Grant
Filed:
April 13, 2018
Date of Patent:
September 19, 2023
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Abstract: The invention disclosed herein is for an in vitro cell-based assay for predicting the conversion from mild cognitive impairment to Alzheimer's disease in a patient who has received a diagnosis of MCI. The method comprises the following steps: a) culturing human hippocampal progenitor cells in a culture medium comprising serum, obtained from said patient, during a period of proliferation of said progenitor cells; b) subsequently culturing said hippocampal progenitor cells in a culture medium comprising serum, obtained from said patient, during a period of differentiation of said progenitor cells; c) determining the level of proliferation of said cultured progenitor cells; d) determining the average cell count of said cultured progenitor cells; and e) monitoring apoptotic cell death after differentiation of the proliferated hippocampal progenitor cells, wherein the outcomes of each of (c) to (e) are applied to a statistical analysis, the result of which is predictive of conversion from MCI to AD in the patient.
Type:
Grant
Filed:
September 28, 2017
Date of Patent:
September 5, 2023
Assignee:
King's College London
Inventors:
Sandrine Thuret-Hindges, Simon Lovestone, Jack Price, Aleksandra Maruszak, Tytus Murphy
Abstract: Provided herein are methods for identifying and treating BAV disease and/or aortopathy in a subject, and methods of improving outcome in a subject. The subject may be asymptomatic of BAV disease and/or aortopathy, experiencing symptoms of BAV disease and/or aortopathy, have BAV disease and/or aortopathy, or be a blood relative of an individual having BAV disease and/or aortopathy. Levels of sRAGE in the subject's biological sample are determined, compared to a control biological sample, and used as an indicator for the presence and severity of BAV disease and/or aortopathies, a tool to screen family members, and an indicator of the proper surgical or treatment regimens.
Type:
Grant
Filed:
June 3, 2014
Date of Patent:
June 6, 2023
Assignee:
The Trustees of the University of Pennsylvania
Abstract: The present invention relates to a composition which comprises peptides derived from S-Arrestin (retinal arrestin, S-antigen, S-Ag). The composition or peptides may be useful in the prevention and/or suppression of S-Ag autoimmunity, which is useful in the treatment and/or prevention of uveitis.
Abstract: Provided herein are antibodies that specifically bind a protein comprising an H1.0K180me2 antigen or a peptide thereof, methods of making such antibodies, and methods of using such antibodies for therapeutics and diagnostics.
Type:
Grant
Filed:
April 23, 2020
Date of Patent:
November 22, 2022
Assignee:
AELAN CELL TECHNOLOGIES, INC.
Inventors:
Victoria V. Lunyak, James Robert Tollervey
Abstract: Compositions are disclosed which include a CAQK peptide linked or conjugated to a cargo composition, where the peptide selectively homes the composition to a site of nervous system injury in a subject.
Type:
Grant
Filed:
April 27, 2020
Date of Patent:
October 4, 2022
Assignee:
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Inventors:
Erkki Ruoslahti, Aman Mann, Pablo Scodeller, Sazid Hussain
Abstract: This invention relates to the prevention and treatment of neurodegenerative diseases by administering compositions that increase the activity of a small proline-rich repeat 1 A protein (Sprr1A), or derivative thereof to the brain. Specifically, the compositions may comprise a nucleic acid molecule encoding a Sprr1A protein or a biologically-active portion thereof. The neurodegenerative disease may be Parkinson's Disease, Alzheimer's disease, amyotrophic lateral sclerosis, or traumatic brain injury.
Type:
Grant
Filed:
August 27, 2015
Date of Patent:
September 6, 2022
Assignee:
Board of Trustees of Michigan State University
Inventors:
Jack W. Lipton, Nicholas Kanaan, Timothy Collier
Abstract: This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.
Abstract: Antibodies specific for secretogranin III (Scg3) are disclosed. Methods of using the antibodies, antigen-binding fragments thereof, or pharmaceutical compositions comprising the same in the treatment of diseases such as diabetic retinopathy, neovascular age-related macular degeneration, retinopathy of prematurity, and cancer, are also disclosed.
Type:
Grant
Filed:
November 6, 2017
Date of Patent:
August 16, 2022
Assignee:
UNIVERSITY OF MIAMI
Inventors:
Wei Li, Michelle E. Leblanc, Weiwen Wang, Philip J. Rosenfeld
Abstract: Methods of expressing a neuropeptide in a neuron of a subject are described. Methods of altering a behavior in a subject in need thereof are described. Kits are described. Vectors are described.
Abstract: The composition of the present invention can inhibit homologous human T cell reaction and the phenomenon of infiltration which reduces skin graft damage in vivo, thereby enabling prompt, rapid and effective graft rejection prevention or treatment effects at a low concentration. In addition, the present invention has advantages of successfully controlling in vivo human T cell reactions, as compared with conventional therapeutic agents, thus providing few side effects, the possibilities of local high-dose administration of therapeutic agents and potentially new treatments and prescriptions.
Type:
Grant
Filed:
August 19, 2019
Date of Patent:
June 7, 2022
Assignee:
IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY)
Abstract: This present invention provides a method for continuously maintaining growth of a motor neuron progenitor cell and a pharmaceutical composition. Wherein, the method for continuously maintaining growth of a motor neuron progenitor cell is to culture the motor neuron progenitor cell in an environment which is constructed by the olfactory ensheathing cells to make the motor neuron progenitor cell sustain the ability to self-replicate and to be induced for differentiating into mature neuron, and therefore to elaborate the effect to protect the motor neuron. The motor neuron progenitor cell produced from the method disclosed in this present invention can be an effective ingredient of the pharmaceutical composition for treating related diseases of damaged motor neuron.
Abstract: The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like. The present invention also provides assays using transgenic Nestin/Ramp1 rodents, utilizing a CGRP model light aversive behavior model for identifying therapeutically effective anti-CGRP antibodies and fragments thereof having binding specificity for CGRP which inhibit or prevent photophobia in subjects in need thereof. The present invention is specifically directed to methods for identifying therapeutically effective antibodies and fragments thereof having binding specificity for CGRP that may be used to treat CGRP associated disorders such as migraine.
Type:
Grant
Filed:
April 18, 2019
Date of Patent:
May 10, 2022
Assignees:
H. LUNDBECK A/S, THE UNIVERSITY OF IOWA RESEARCH FOUNDATION
Inventors:
Andrew F. Russo, Eric A. Kaiser, Ana Recober, Adisa Kuburas, Ann C. Raddant, Brian R. Kovacevich, John Latham, Jeffrey T. L. Smith, Leon F. Garcia-Martinez
Abstract: The present disclosure provides compositions and methods for treating subjects at risk for or with sensorineural hearing loss by modulating the rate of Atoh1 protein degradation to increase levels of Atoh1 protein.
Type:
Grant
Filed:
March 19, 2019
Date of Patent:
March 29, 2022
Assignee:
Massachusetts Eye and Ear Infirmary
Inventors:
Albert Edge, Yen-Fu Cheng, Judith Kempfle, Dunia Abdul-Aziz
Abstract: Disclosed is the use of genetic means or a related inhibitor to inhibit and down-regulate the amount of PI4KIII? protein, RBO/EFR3/EFR3A/EFR3B membrane proteins, TTC7 protein and membrane protein complexes formed by said proteins, or related enzyme activity to promote A? secretion by neuronal cells, reduce A? accumulation within neurons, and thereby reduce AD model fruit fly and mouse nerve dysfunction.
Abstract: There is provided in the present application a peptide comprising the amino acid sequence of YEKLLDTEI (SEQ ID NO: 1) or a functional variant thereof. The peptide is an active peptide for the treatment of a central nervous system injury. The present application also provides a chimeric peptide comprising an active peptide and an internalization peptide. The present application also provides a pharmaceutical composition comprising the active peptide or the chimeric peptide, as well as medical use of the active peptide or the chimeric peptide.